Israeli company plans to make insulin injections obsolete
Kadimastem aims to render needles a thing of the past for diabetes patients by developing a stem-cell mechanism that creates insulin in the body.
Kadimastem aims to render needles a thing of the past for diabetes patients by developing a stem-cell mechanism that creates insulin in the body.
Close to $850 million poured into Israeli firms in June 2017 to advance pharma, cybersecurity, e-commerce, autonomous-vehicle and other technologies.
Israel’s Kadimastem is testing its technology for differentiating pluripotent stem cells into a range of functional human cells.